Abstract: The invention provides an adaptor for a medicament delivery device is configured to enable a set dosage of a medicament to be drawn into and/or expelled from the device, the adaptor including: a body configured to be coupled to the device; an attachment portion movable with respect to the body and configured for attachment with a first part of the device; an engaging portion movable with the attachment portion; and a receiver configured to receive a movement constraint guide (MCG) and facilitate engagement between the engaging portion and the MCG; wherein the MCG includes one or more physical features defining at least an aspect of the set dosage; and wherein activation of said first part of the device to draw and/or expel the medicament is stopped when the set dosage is reached by engagement between the engaging portion and at least one of the one or more physical features of the MCG.

Abstract: A multi-source power supply for supplying power that includes a first rectifier configured to convert a first AC power signal from a first source to a first DC power signal, a second rectifier configured to convert a second AC power signal from a second source to a second DC power signal and a common bus operatively connected to the first rectifier and the second rectifier and configured to combine a the DC power signals into a combined DC power signal, where the common bus distributes the combined DC power signal to at least one server.

Abstract: A multi-source power supply for supplying power that includes a first rectifier configured to convert a first AC power signal from a first source to a first DC power signal, a second rectifier configured to convert a second AC power signal from a second source to a second DC power signal and a common bus operatively connected to the first rectifier and the second rectifier and configured to combine a the DC power signals into a combined DC power signal, where the common bus distributes the combined DC power signal to at least one server.

Abstract: A system is provided to allow for charging of a chemical storage device without a rectifier. A gate is used in conjunction with a gate controller. The gate controller monitors input voltage and opens the gate when voltage crosses a zero crossing in a first direction. The gate monitor then closes the gate when the voltage crosses a zero crossing in a second direction. This increases the chances that the output power will have voltage in a single direction. This output power is then fed to a chemical storage device, where it can be stored and used by one or more electronic devices.

Abstract: A multi-source power supply for supplying power that includes a first rectifier configured to convert a first AC power signal from a first source to a first DC power signal, a second rectifier configured to convert a second AC power signal from a second source to a second DC power signal and a common bus operatively connected to the first rectifier and the second rectifier and configured to combine a the DC power signals into a combined DC power signal, where the common bus distributes the combined DC power signal to at least one server.

Abstract: A system is provided to allow for charging of a chemical storage device without a rectifier. A gate is used in conjunction with a gate controller. The gate controller monitors input voltage and opens the gate when voltage crosses a zero crossing in a first direction. The gate monitor then closes the gate when the voltage crosses a zero crossing in a second direction. This increases the chances that the output power will have voltage in a single direction. This output power is then fed to a chemical storage device, where it can be stored and used by one or more electronic devices.

Abstract: A system is provided to allow for charging of a chemical storage device without a rectifier. A gate is used in conjunction with a gate controller. The gate controller monitors input voltage and opens the gate when voltage crosses a zero crossing in a first direction. The gate monitor then closes the gate when the voltage crosses a zero crossing in a second direction. This increases the chances that the output power will have voltage in a single direction. This output power is then fed to a chemical storage device, where it can be stored and used by one or more electronic devices.

Abstract: A system is provided to allow for charging of a chemical storage device without a rectifier. A gate is used in conjunction with a gate controller. The gate controller monitors input voltage and opens the gate when voltage crosses a zero crossing in a first direction. The gate monitor then closes the gate when the voltage crosses a zero crossing in a second direction. This increases the chances that the output power will have voltage in a single direction. This output power is then fed to a chemical storage device, where it can be stored and used by one or more electronic devices.

Abstract: The invention provides pharmaceutical compositions and method for inhibiting growth of prostatic adenocarcinoma, stomach cancer, breast cancer, endometrial, ovarian or other cancers of epithelial secretion, or benign prostate hyperplasia (BPH). In one embodiment the pharmaceutical composition includes human rHuPSP94, antigenic portions thereof, and functionally equivalent polypeptides thereof. In another embodiment, the pharmaceutical composition includes a mixture of human rHuPSP94, antigenic portions thereof, and functionally equivalent polypeptides thereof and an anticancer drug which may be administered in an appropriate dosage form, dosage quantity and dosage regimen to a patient suffering from, for example of prostatic adenocarcinoma, stomach cancer, breast cancer, endometrial, ovarian or other cancers of epithelial secretion, benign prostate hyperplasia, or (BPH) gastrointestinal cancer.

Abstract: The invention provides pharmaceutical compositions and method for inhibiting growth of prostatic adenocarcinoma, stomach cancer, breast cancer, endometrial, ovarian or other cancers of epithelial secretion, or benign prostate hyperplasia (BPH). In one embodiment the pharmaceutical composition includes human rHuPSP94, antigenic portions thereof, and functionally equivalent polypeptides thereof. In another embodiment, the pharmaceutical composition includes a mixture of human rHuPSP94, antigenic portions thereof, and functionally equivalent polypeptides thereof and an anticancer drug which may be administered in an appropriate dosage form, dosage quantity and dosage regimen to a patient suffering from, for example of prostatic adenocarcinoma, stomach cancer, breast cancer, endometrial, ovarian or other cancers of epithelial secretion, benign prostate hyperplasia, or (BPH) gastrointestinal cancer.

Abstract: The invention provides pharmaceutical compositions and method for inhibiting growth of prostatic adenocarcinoma, stomach cancer, breast cancer, endometrial, ovarian or other cancers of epithelial secretion, or benign prostate hyperplasia (BPH) In one embodiment the pharmaceutical composition includes human rHuPSP94, antigenic portions thereof, and functionally equivalent polypeptides thereof. In another embodiment, the pharmaceutical composition includes a mixture of human rHuPSP94, antigenic portions thereof, and functionally equivalent polypeptides thereof and an anticancer drug which may be administered in an appropriate dosage form, dosage quantity and dosage regimen to a patient suffering from, for example of prostatic adenocarcinoma, stomach cancer, breast cancer, endometrial, ovarian or other cancers of epithelial secretion, benign prostate hyperplasia, or (BPH) gastrointestinal cancer.

Abstract: The invention provides pharmaceutical compositions and method for inhibiting growth of prostatic adenocarcinoma, stomach cancer, breast cancer, endometrial, ovarian or other cancers of epithelial secretion, or benign prostate hyperplasia (BPH). In one embodiment the pharmaceutical composition includes human rHuPSP94, antigenic portions thereof, and functionally equivalent polypeptides thereof. In another embodiment, the pharmaceutical composition includes a mixture of human rHuPSP94, antigenic portions thereof, and functionally equivalent polypeptides thereof and an anticancer drug which may be administered in an appropriate dosage form, dosage quantity and dosage regimen to a patient suffering from, for example of prostatic adenocarcinoma, stomach cancer, breast cancer, endometrial, ovarian or other cancers of epithelial secretion, benign prostate hyperplasia, or (BPH) gastrointestinal cancer.

Abstract: The invention provides pharmaceutical compositions and method for inhibiting growth of prostatic adenocarcinoma, stomach cancer, breast cancer, endometrial, ovarian or other cancers of epithelial secretion, or benign prostate hyperplasia (BPH) In one embodiment the pharmaceutical composition includes human rHuPSP94, antigenic portions thereof, and functionally equivalent polypeptides thereof. In another embodiment, the pharmaceutical composition includes a mixture of human rHuPSP94, antigenic portions thereof, and functionally equivalent polypeptides thereof and an anticancer drug which may be administered in an appropriate dosage form, dosage quantity and dosage regimen to a patient suffering from, for example of prostatic adenocarcinoma, stomach cancer, breast cancer, endometrial, ovarian or other cancers of epithelial secretion, benign prostate hyperplasia, or (BPH) gastrointestinal cancer.

Abstract: When a content of an on-screen item representing a feature of an application program is changed without user's direct interaction, the present invention provides a visual cue that indicates the content change of the on-screen item to help attracting user's attention to the change.

Abstract: An anchor manager is described for providing a window for presenting window contents. It comprises a pane provider, an anchor indicator and a coupler. The pane provider provides multiple panes, each containing window contents. The anchor indicator provider provides multiple anchor indicators, each representing its related window contents. The coupler associates an anchor indicator to a pane that contains window contents represented by the anchor indicator so as to allow display of the panes in a display area of the window according to selection of the anchor indicators.

Abstract: The invention provides pharmaceutical compositions and method for inhibiting growth of prostatic adenocarcinoma, stomach cancer, breast cancer, endometrial, ovarian or other cancers of epithelial secretion, or benign prostate hyperplasia (BPH). In one embodiment the pharmaceutical composition includes human rHuPSP94, antigenic portions thereof, and functionally equivalent polypeptides thereof. In another embodiment, the pharmaceutical composition includes a mixture of human rHuPSP94, antigenic portions thereof, and functionally equivalent polypeptides thereof and an anticancer drug which may be administered in an appropriate dosage form, dosage quantity and dosage regimen to a patient suffering from, for example of prostatic adenocarcinoma, stomach cancer, breast cancer, endometrial, ovarian or other cancers of epithelial secretion, benign prostate hyperplasia, or (BPH) gastrointestinal cancer.